Pylum has developed a portfolio of therapeutic protein candidates that destroy target cells with surgical precision. Its new class of narrow-spectrum bacteria-killing agents is a potential solution to overcome two important complications of broad-spectrum antibiotics: the rampant spread of drug resistance and the collateral damage to the healthy, protective bacteria that constitute the microbiota.